...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Novel effects of macrostemonoside A, a compound from Allium macrostemon Bung, on hyperglycemia, hyperlipidemia, and visceral obesity in high-fat diet-fed C57BL/6 mice.
【24h】

Novel effects of macrostemonoside A, a compound from Allium macrostemon Bung, on hyperglycemia, hyperlipidemia, and visceral obesity in high-fat diet-fed C57BL/6 mice.

机译:高脂饮食C57BL / 6小鼠中的巨硬糖甙A(一种来自葱属大葱的化合物)对高血糖,高血脂和内脏肥胖的新型作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Macrostemonoside A, a newly found compound, is derived from Allium macrostemon Bung. However, investigation into its nature is lacking. In this study, the effects of macrostemonoside A on hyperglycemia, hyperlipidemia, visceral fat accumulation, and related enzyme activities in high-fat diet-fed C57BL/6 mice are examined. The results showed that mice fed with a high-fat diet had a significant increase in fasting blood glucose, liver glycogen, serum total cholesterol, and visceral fat accumulation, but were mildly or moderately inhibited by macrostemonoside A at a dose of 4 mg/kg/d after 30 days of treatment. This hypoglycemic effect might be associated with the potential increase in insulin sensitivity and visfatin expression, although it needs further validation in future studies. Its anti-obesity effect might be associated with elevated total lipase activity in visceral adipose cells. The up-regulation in the expression of peroxisome proliferators-activated receptor gamma 2 might be responsible for the increased lipase activity in visceral adipose cells. Furthermore, we supposed that its action mechanisms might promote energy metabolism in muscles. Macrostemonoside A, with its steroid-like structure, has no significant cortisone-like side effects on the immune system but has potential cardiovascular protective effects. These results suggested that a potential compound to treat hyperglycemia, hyperlipidemia, and visceral obesity could be developed. However, its underlying mechanisms need further investigation in future studies.
机译:新发现的大叶菊糖苷A是从葱属大葱中提取的。但是,缺乏对其性质的调查。在这项研究中,检查了大果菊糖苷A对高脂饮食喂养的C57BL / 6小鼠的高血糖,高血脂,内脏脂肪蓄积和相关酶活性的影响。结果表明,高脂饮食喂养的小鼠的空腹血糖,肝糖原,血清总胆固醇和内脏脂肪蓄积显着增加,但是在剂量为4 mg / kg的大麦甜菊糖苷A中有轻度或中度抑制作用/ d治疗30天后。这种降血糖作用可能与胰岛素敏感性和visfatin表达的潜在增加有关,尽管在未来的研究中需要进一步验证。它的抗肥胖作用可能与内脏脂肪细胞中总脂肪酶活性升高有关。过氧化物酶体增殖物激活的受体γ2的表达上调可能是内脏脂肪细胞脂肪酶活性增加的原因。此外,我们认为其作用机制可能促进肌肉能量代谢。 Macrostemonoside A具有类固醇的结构,对免疫系统没有明显的可的松样副作用,但具有潜在的心血管保护作用。这些结果表明可以开发出治疗高血糖,高血脂和内脏肥胖的潜在化合物。但是,其潜在的机制需要在未来的研究中进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号